Report Library
All ReportsDatamonitor Schizophrenia KOL Interview
February 10, 2016
Datamonitor interviewed a psychiatrist based in Hamburg, Germany to determine his current treatment practices and opinions on late-stage pipeline drugs for the treatment of schizophrenia.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only). Highlights
- KOL believes that tolerability is the number one factor he considers when prescribing treatment for schizophrenia.
- He feels that long-acting injectables are currently underutilized, even more so in the US than the EU.
- He expects that only 20-40% of patients would switch from 1-month paliperidone to 3-month paliperidone upon its approval (JNJ).
- Cariprazine is a promising candidate particularly with negative symptoms but will have to show significant advantages to use in the EU due to the higher cost compared to generic atypicals (AGN).
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: | Schizophrenia |
Additional Resources: